RESUMEN

Regulation of the p73 gene is complex due to the presence of two promoters and the very complex mRNA maturation in both the N-terminal and C-terminal parts of the protein. We have found an additional regulation mechanism for the p73-alpha form that occurs through proteolytic cleavage connected to the activity of the serine protease HtrA2. Following apoptotic stimuli, HtrA2 accumulates in the nucleus and cleaves p73alpha in the C-terminal portion, enabling the protein to increase its transactivation activity on the apoptotic gene bax but not on the cell-cycle regulator gene p21. In the presence of HtrA2, p73 is more prone to cause caspase activation and nuclei fragmentation: p73 needs HtrA2 to activate and enhance its apoptotic functions. This new relation between p73 and HtrA2 may help to understand the different behavior of the p73 protein in cell physiology and in the responses of cancer cells to chemotherapy.

Asunto(s)

Apoptosis/fisiología , Proteínas de Unión al ADN/metabolismo , Regulación de la Expresión Génica , Proteínas Mitocondriales/metabolismo , Proteínas Nucleares/metabolismo , Serina Endopeptidasas/metabolismo , Proteínas Supresoras de Tumor/metabolismo , Proteína X Asociada a bcl-2 , Línea Celular Tumoral , Núcleo Celular/metabolismo , Inhibidor p21 de las Quinasas Dependientes de la Ciclina/genética , Inhibidor p21 de las Quinasas Dependientes de la Ciclina/metabolismo , Proteínas de Unión al ADN/genética , Serina Peptidasa A2 que Requiere Temperaturas Altas , Humanos , Proteínas Mitocondriales/genética , Proteínas Nucleares/genética , Regiones Promotoras Genéticas , Isoformas de Proteínas/genética , Isoformas de Proteínas/metabolismo , ARN Interferente Pequeño/genética , ARN Interferente Pequeño/metabolismo , Serina Endopeptidasas/genética , Proteína Tumoral p73 , Proteínas Supresoras de Tumor/genética , Proteína X Asociada a bcl-2/genética , Proteína X Asociada a bcl-2/metabolismo

RESUMEN

Activation of c-Jun, a component of the AP-1 family of transcription factors, leads to either promotion or prevention of apoptosis. However, the molecular determinants of c-Jun-mediated cell survival are still unclear. We show here that inducible expression of c-Jun promotes cellular survival by negatively regulating the expression of the tumor-suppressor PTEN, resulting in the concomitant activation of the Akt survival pathway. Consistently, c-jun-/- fibroblasts, which are sensitive to nutrient deprivation, and human cell lines in which c-Jun expression is silenced, express elevated levels of PTEN. siRNA-mediated silencing of PTEN resulted in the reduction of cell-death owing to c-Jun deficiency. c-Jun was found to suppress PTEN expression by binding to a variant AP-1 site found in the 5' upstream sequences of PTEN promoter. Finally, an inverse correlation between c-Jun and PTEN levels was apparent in a panel of human tumor cell lines, independent of their p53 status. Together, the data demonstrate that c-Jun contributes to the promotion of cellular survival by regulating the expression of PTEN.

Asunto(s)

Fosfohidrolasa PTEN/metabolismo , Proteínas Proto-Oncogénicas c-jun/metabolismo , Animales , Secuencia de Bases , Sitios de Unión , Muerte Celular , Línea Celular Tumoral , Supervivencia Celular , Activación Enzimática , Privación de Alimentos , Regulación Neoplásica de la Expresión Génica , Silenciador del Gen , Humanos , Ratones , Datos de Secuencia Molecular , Células 3T3 NIH , Fosfohidrolasa PTEN/genética , Proteínas Proto-Oncogénicas c-akt/metabolismo , Proteínas Proto-Oncogénicas c-jun/deficiencia , ARN Mensajero/genética , ARN Mensajero/metabolismo , ARN Interferente Pequeño/metabolismo , Factor de Transcripción AP-1/genética

RESUMEN

The p73 gene has a complex regulation, which leads to the expression of different isoforms, often with opposite biological effects. We have generated in the human colocarcinoma cell line HCT116, expressing a wild-type p53, an inducible DNp73alpha expressing system. Two clones (HCT116/DN3 and HCT116/DN14), upon doxycycline addition, show a strong expression of DNp73alpha. In vitro the two DNp73alpha overexpressing clones grow at similar rate of the control transfected clone (HCT116/8a) and similarly respond to DNA damage. When injected in mice, HCT116/DN3, HCT116/DN14, and HCT116/8a cells grew similarly in the absence or presence of tetracycline. In HCT116/DN3 and HCT116/DN14 tumors, tetracycline induced a strong expression of DNp73alpha both as mRNA and protein. These results indicate that in this system the overexpression of the DNp73alpha does not induce a more aggressive phenotype and does not seem to be associated with a reduced response of the cells to treatment with anticancer agents.

Asunto(s)

Proteínas de Unión al ADN/genética , Proteínas de Unión al ADN/metabolismo , Neoplasias/tratamiento farmacológico , Neoplasias/patología , Proteínas Nucleares/genética , Proteínas Nucleares/metabolismo , Animales , Antibióticos Antineoplásicos/farmacología , Proliferación Celular/efectos de los fármacos , Daño del ADN/efectos de los fármacos , Doxorrubicina/farmacología , Doxiciclina/farmacología , Expresión Génica , Genes Supresores de Tumor , Células HCT116 , Humanos , Ratones , Neoplasias/genética , Fenotipo , Proteína Tumoral p73 , Proteínas Supresoras de Tumor

RESUMEN

Tumor neovascularization is controlled by a balance between positive and negative effectors, whose production can be regulated by oncogenes and tumor suppressor genes. The aim of this study was to investigate whether the angiogenic potential of tumors could also be controlled by p73, a gene homologous to the tumor suppressor p53, whose involvement in tumor angiogenesis is known. We have studied the production of proangiogenic (VEGF, FGF-2, PIGF and PDGF) and antiangiogenic (TSP-1) factors in two p73 overexpressing clones obtained from the human ovarian carcinoma cells A2780. TSP-1 was downregulated in both clones compared to mock transfected cells, both at mRNA and protein level. Conversely, both clones showed an increased production of VEGF mRNA and protein. For both TSP-1 and VEGF, regulation of expression was partially due to modulation of the promoter activity, and was dependent on p53 status. Production of the other angiogenic factors FGF-2, PIGF and PDGF-B was also increased in p73 overexpressing clones. The two clones were more angiogenic than parental cells, as shown in vitro by their increased chemotactic activity for endothelial cells, and in vivo by the generation of more vascularized tumors. These findings suggest a potential role of p73 in tumor angiogenesis.

Asunto(s)

Proteínas de Unión al ADN/fisiología , Factores de Crecimiento Endotelial/biosíntesis , Linfocinas/biosíntesis , Neovascularización Patológica/genética , Proteínas Nucleares/fisiología , Trombospondina 1/biosíntesis , Animales , Northern Blotting , Carcinoma/patología , Quimiotaxis/efectos de los fármacos , Medios de Cultivo Condicionados/química , Medios de Cultivo Condicionados/farmacología , Medio de Cultivo Libre de Suero , Proteínas de Unión al ADN/biosíntesis , Proteínas de Unión al ADN/genética , Factores de Crecimiento Endotelial/genética , Endotelio Vascular/citología , Ensayo de Inmunoadsorción Enzimática , Femenino , Factor 2 de Crecimiento de Fibroblastos/biosíntesis , Factor 2 de Crecimiento de Fibroblastos/genética , Regulación Neoplásica de la Expresión Génica , Genes Supresores de Tumor , Genes p53 , Humanos , Linfocinas/genética , Proteínas de la Membrana , Ratones , Ratones Desnudos , Proteínas de Neoplasias/biosíntesis , Proteínas de Neoplasias/genética , Trasplante de Neoplasias , Neoplasias Experimentales/irrigación sanguínea , Neovascularización Patológica/metabolismo , Proteínas Nucleares/biosíntesis , Proteínas Nucleares/genética , Neoplasias Ováricas/patología , Factor de Crecimiento Derivado de Plaquetas/biosíntesis , Factor de Crecimiento Derivado de Plaquetas/genética , Regiones Promotoras Genéticas , Biosíntesis de Proteínas , Proteínas/genética , ARN Mensajero/biosíntesis , ARN Neoplásico/biosíntesis , Proteínas Recombinantes de Fusión/fisiología , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Trombospondina 1/genética , Transfección , Células Tumorales Cultivadas/efectos de los fármacos , Células Tumorales Cultivadas/metabolismo , Proteína Tumoral p73 , Proteína p53 Supresora de Tumor/fisiología , Proteínas Supresoras de Tumor , Factor A de Crecimiento Endotelial Vascular , Factores de Crecimiento Endotelial Vascular

RESUMEN

Posttranslational modifications of p53 induced by two widely used anticancer agents, cisplatinum (DDP) and taxol were investigated in two human cancer cell lines. Although both drugs were able to induce phosphorylation at serine 20 (Ser20), only DDP treatment induced p53 phosphorylation at serine 15 (Ser15). Moreover, both drug treatments were able to increase p53 levels and consequently the transcription of waf1 and mdm-2 genes, although DDP treatment resulted in a stronger inducer of both genes. Using two ataxia telangiectasia mutated (ATM) cell lines, the role of ATM in drug-induced p53 phosphorylations was investigated. No differences in drug-induced p53 phosphorylation could be observed, indicating that ATM is not the kinase involved in these phosphorylation events. In addition, inhibition of DNA-dependent protein kinase activity by wortmannin did not abolish p53 phosphorylation at Ser15 and Ser20, again indicating that DNA-PK is unlikely to be the kinase involved. After both taxol and DDP treatments, an activation of hCHK2 was found and this is likely to be responsible for phosphorylation at Ser20. In contrast, only DDP was able to activate ATR, which is the candidate kinase for phosphorylation of Ser15 by this drug. This data clearly suggests that differential mechanisms are involved in phosphorylation and activation of p53 depending on the drug type.

Asunto(s)

Antineoplásicos Fitogénicos/farmacología , Antineoplásicos/farmacología , Cisplatino/farmacología , Proteínas de Unión al ADN , Proteínas Quinasas Activadas por Mitógenos/metabolismo , Proteínas Nucleares , Paclitaxel/farmacología , Células Tumorales Cultivadas/metabolismo , Proteína p53 Supresora de Tumor/metabolismo , Androstadienos/farmacología , Proteínas de la Ataxia Telangiectasia Mutada , Western Blotting , Proteínas de Ciclo Celular/metabolismo , Neoplasias del Colon/metabolismo , Inhibidor p21 de las Quinasas Dependientes de la Ciclina , Ciclinas/metabolismo , Proteína Quinasa Activada por ADN , Femenino , Humanos , Neoplasias Ováricas/metabolismo , Inhibidores de las Quinasa Fosfoinosítidos-3 , Fosforilación , Procesamiento Proteico-Postraduccional , Proteínas Serina-Treonina Quinasas/metabolismo , Proteínas Proto-Oncogénicas/metabolismo , Proteínas Proto-Oncogénicas c-mdm2 , Transcripción Genética , Células Tumorales Cultivadas/efectos de los fármacos , Wortmanina

RESUMEN

We examined the consequences of p73alpha overexpression on gene expression and cellular response to anticancer agents in clones from the human ovarian cancer cell line A2780. Using microarray filters, the expression of 588 genes in two clones overexpressing p73alpha (A2780/p73.4 and A2780/ p73.5) in comparison with empty vector-transfected cells was evaluated. There were clear differences in gene expression profiles. Both of the clones showed a marked increase in the expression of genes involved in DNA repair, including genes participating in nucleotide excision repair and mismatch repair. This was confirmed by reverse transcription-PCR and Northern blot analysis and was associated with an increase in the ability of p73alpha-expressing clones to repair two different DDP (cis-dichlorodiammine platinum)-damaged plasmids in a host reactivation assay. p73alpha overexpressing clones were less sensitive than parental cells to alkylating agents treatment or UV radiation but equally sensitive to the topoisomerase I inhibitor topotecan, which indicated that the increase in expression of DNA repair genes has implications for the response to DNA damaging agents.

Asunto(s)

Daño del ADN , Proteínas de Unión al ADN/biosíntesis , Proteínas Nucleares/biosíntesis , Neoplasias Ováricas/genética , Neoplasias Ováricas/metabolismo , División Celular , Cisplatino/farmacología , Células Clonales , Reparación del ADN/genética , Proteínas de Unión al ADN/genética , Resistencia a Antineoplásicos , Femenino , Expresión Génica , Perfilación de la Expresión Génica , Regulación Neoplásica de la Expresión Génica , Genes Supresores de Tumor , Humanos , Proteínas Nucleares/genética , Neoplasias Ováricas/tratamiento farmacológico , ARN Mensajero/genética , ARN Mensajero/metabolismo , Topotecan/farmacología , Transfección , Células Tumorales Cultivadas , Proteína Tumoral p73 , Proteína p53 Supresora de Tumor/biosíntesis , Proteína p53 Supresora de Tumor/genética , Proteínas Supresoras de Tumor , Rayos Ultravioleta/efectos adversos

RESUMEN

The tumor suppressor gene tp53 is mutated, deleted, or rearranged in more than 50% of human tumors (1). Wild-type (wt) tp53 stops growth and/or induces apoptosis in most transformed cells into which it is introduced, thus restricting research of such cells. One means of studying the effects of both wt and mutant tp53 is to generate cells in which tp53 activity can be experimentally manipulated using inducible transcriptional control elements to drive wt tp53 expression (2-4). Alternatively, temperature-sensitive (ts) tp53 mutants may be used. Such mutants were first analyzed by Oren (5) and possess wt tp53 activity at 32°C, but behave like other mutants tp53 molecules at 37°C.

RESUMEN

The transcriptional activity of the p53 tumor suppressor protein is crucial for the regulation of cell growth, apoptosis and tumor progression. The first identified p53 relative, p73, was reported to be monoallelically expressed in normal tissues. In some tumors, loss of heterozygosity was associated with overexpression of the silent allele. Human p73alpha was transfected into the wild-type p53-expressing human ovarian carcinoma cell line A2780. Unlike human osteosarcoma Saos-2 cells, A2780 cells could tolerate hyperexpression of p73alpha and clones over-expressing p73alpha could be isolated. No p53-p73 protein-protein interaction was found in these clones in co-immunoprecipitation experiments. Endogenous p53 transcriptional activity was markedly decreased both when p73 was integrated into the genome and in transient transfections using a reporter plasmid containing the p53 binding site linked to luciferase. Transient transfection of p73 with a mutation in the DNA-binding domain did not show these effects. The competition for p53 DNA binding by p73alpha was also evident in gel shift experiments. The results suggest that p73 can modulate p53 function by inhibiting its DNA binding and that overexpression of p73 in tumors might be a novel mechanism of inactivation of p53.

Asunto(s)

Proteínas de Unión al ADN/metabolismo , Genes Supresores de Tumor , Proteínas Nucleares/metabolismo , Neoplasias Ováricas/patología , Proteína p53 Supresora de Tumor/metabolismo , Sitios de Unión , Cisplatino/farmacología , ADN de Neoplasias/metabolismo , Proteínas de Unión al ADN/genética , Doxorrubicina/farmacología , Femenino , Regulación Neoplásica de la Expresión Génica/efectos de los fármacos , Humanos , Proteínas Nucleares/genética , Neoplasias Ováricas/genética , Paclitaxel/farmacología , Pruebas de Precipitina , Transcripción Genética/efectos de los fármacos , Transfección , Células Tumorales Cultivadas , Proteína Tumoral p73 , Proteína p53 Supresora de Tumor/genética , Proteínas Supresoras de Tumor

RESUMEN

We have studied the possible interactions between the mismatch repair system and p53 in a human colon cancer cell line, HCT-116 (known to have a homozygous mutation in mismatch repair gene hMLH1 on chromosome 3) and in a clone obtained after insertion of a single copy of chromosome 3 (HCT-116+ ch3). Loss of DNA mismatch repair activity resulted in resistance to cisplatin (DDP). p53 accumulated differently in these cell lines after treatment with DDP. Initially at similar high levels after DDP treatment, p53 maintained the increase in HCT-116 cells, even 72-96 h after drug exposure, whereas HCT-116+ch3 mismatch-proficient cell line p53 declined to basal levels after 48 h. The higher levels of p53 in mismatch-deficient HCT-116 cells were accompanied by increased transcriptional activity as assessed by the gel-retardation assay and by activation of a promoter containing a p53 DNA binding site. To better understand the role of p53, if any, in cell sensitivity to DDP, we disrupted p53 in both cell lines by stable transfection with the human papillomavirus type 16 E6 gene. HCT-116/E6 cells were more sensitive to DDP than the parental cell line, whereas HCT-116+ch3/E6 were fairly similar to HCT-116+ch3 with normal p53 function. Although in our system the transfer of the entire chromosome 3 was used (thus not excluding a possible role of other genes localized on this chromosome), our data indicate that p53 can cooperate with the mismatch repair system. In fact, the lack of hLMH1, at least in these cells, enhances the role of p53 in protecting the cells from DDP-induced DNA damage.

Asunto(s)

Adenocarcinoma/metabolismo , Neoplasias del Colon/metabolismo , Reparación del ADN/genética , Proteínas de Neoplasias/fisiología , Proteínas Represoras , Proteína p53 Supresora de Tumor/metabolismo , Proteínas Adaptadoras Transductoras de Señales , Adenocarcinoma/genética , Adenocarcinoma/patología , Disparidad de Par Base/genética , Proteínas Portadoras , Ciclo Celular/efectos de los fármacos , Supervivencia Celular/efectos de los fármacos , Cisplatino/farmacología , Células Clonales , Neoplasias del Colon/genética , Neoplasias del Colon/patología , Inhibidor p21 de las Quinasas Dependientes de la Ciclina , Ciclinas/metabolismo , Daño del ADN/genética , Reparación del ADN/efectos de los fármacos , Humanos , Homólogo 1 de la Proteína MutL , Proteínas de Neoplasias/deficiencia , Proteínas de Neoplasias/genética , Proteínas Nucleares , Proteínas Oncogénicas Virales/genética , Transfección , Células Tumorales Cultivadas , Proteína p53 Supresora de Tumor/genética , Proteína p53 Supresora de Tumor/fisiología

RESUMEN

c-Myc is a nuclear protein with important roles in cell transformation, cell proliferation, and gene transcription. It has been previously shown that a 14-amino acid (aa) modified peptide (H1-S6A,F8A) derived from the helix 1 (H1) carboxylic region of c-Myc can interfere in vitro with specific c-Myc DNA binding. Here, we have linked the above Myc-derived 14-aa peptide to a 16-aa sequence from the third helix of Antennapedia (Int). It has been repeatedly reported that this 16-aa Antennapedia peptide is able to cross mammalian cell membranes and to work as a vector for short peptides. Using fluorescent (dansylated or rhodaminated) peptides, we have shown that the fusion peptide with the Antennapedia fragment (Int-H1-S6A,F8A) but not the c-Myc derived fragment alone (H1-S6A,F8A) was capable of internalization inside MCF-7 human breast cancer cells. Int-H1-S6A,F8A and H1-S6A,F8A were the only two peptides capable of inhibiting coimmunoprecipitation of the c-Myc/Max heterodimer in vitro. We have treated (continuously for 10-11 days) MCF-7 cells with four different peptides: Int, H1-S6A,F8A, Int-H1-S6A,F8A, and Int-H1wt [a peptide differing from Int-H1-S6A,F8A by 2 aa (S6 and F8) in the H1 region]. In intact MCF-7 cells, Int-H1-S6A,F8A was the only active peptide capable of inducing the following biological effects: (a) inhibition of cloning efficiency on plates; (b) inhibition of cell growth and induction of apoptosis in subconfluent/confluent cells; and (c) inhibition of transcription of two c-Myc-regulated genes (ODC and p53). Int-H1-S6A,F8A was active in the 1-10 microM range. Int-H1-S6A,F8A may represent a lead molecule for peptidomimetic compounds that have a similar three-dimensional structure but are more resistant to peptidases and, therefore, suitable for in vivo treatment of experimentally induced tumors.

Asunto(s)

Proteínas de Homeodominio/farmacología , Proteínas Nucleares , Fragmentos de Péptidos/farmacología , Proteínas Proto-Oncogénicas c-myc/efectos de los fármacos , Proteínas Recombinantes de Fusión/farmacología , Factores de Transcripción , Secuencia de Aminoácidos , Proteína con Homeodominio Antennapedia , Apoptosis , Factores de Transcripción Básicos con Cremalleras de Leucinas y Motivos Hélice-Asa-Hélice , Factores de Transcripción con Cremalleras de Leucina de Carácter Básico , Adhesión Celular/efectos de los fármacos , Recuento de Células , División Celular/efectos de los fármacos , Proteínas de Unión al ADN/efectos de los fármacos , Proteínas de Unión al ADN/metabolismo , Genes myc/efectos de los fármacos , Proteínas de Homeodominio/química , Proteínas de Homeodominio/metabolismo , Humanos , Datos de Secuencia Molecular , Fragmentos de Péptidos/química , Fragmentos de Péptidos/metabolismo , Proteínas Proto-Oncogénicas c-myc/química , Proteínas Proto-Oncogénicas c-myc/metabolismo , Proteínas Recombinantes de Fusión/química , Proteínas Recombinantes de Fusión/metabolismo , Factores de Tiempo , Células Tumorales Cultivadas/metabolismo , Ensayo de Tumor de Célula Madre

RESUMEN

Paclitaxel-induced cytotoxicity, cell cycle perturbation, and apoptosis were determined in a human ovarian cancer cell line expressing wt p53 (A2780) and in a subclone (A2780/E6) obtained upon transfection with the product of the E6 gene of the human papilloma virus HPV16. The inactivation of wt p53 in A2780/E6 was verified by measuring the inability of the clone to induce p53 and p21 expression after paclitaxel treatment. The p53-negative clone (A2780/E6) was approximately 50-fold more sensitive to paclitaxel than wt p53-expressing A2780 cells. This increased sensitivity was related to the ability of paclitaxel to induce a strong arrest of cells in the G2/M phase of the cell cycle in A2780/E6 but not in A2780 cells. This different cell cycle arrest was accompanied by increased frequency of paclitaxel-induced p53-independent apoptosis. Initial studies on proteases activation tend to exclude a direct role of ICE and CPP32 in the induction of apoptosis in these cells and show a paclitaxel-dependent increase in FLICE levels, whose biological relevance is however at present not defined.

Asunto(s)

Antineoplásicos Fitogénicos/farmacología , Apoptosis/efectos de los fármacos , Caspasas , Fase G2/efectos de los fármacos , Mitosis/efectos de los fármacos , Paclitaxel/farmacología , Proteína p53 Supresora de Tumor/metabolismo , Caspasa 3 , Muerte Celular/efectos de los fármacos , Muerte Celular/fisiología , Núcleo Celular/química , Núcleo Celular/efectos de los fármacos , Núcleo Celular/metabolismo , Cisteína Endopeptidasas/efectos de los fármacos , Cisteína Endopeptidasas/metabolismo , Femenino , Células HL-60/efectos de los fármacos , Células HL-60/enzimología , Humanos , Indoles , Proteína Oncogénica p21(ras)/metabolismo , Proteínas Oncogénicas Virales/genética , Proteínas Oncogénicas Virales/fisiología , Neoplasias Ováricas/tratamiento farmacológico , Neoplasias Ováricas/metabolismo , Neoplasias Ováricas/fisiopatología , Proteínas Recombinantes/genética , Sensibilidad y Especificidad , Transfección , Células Tumorales Cultivadas/efectos de los fármacos

RESUMEN

The expression of mismatch repair proteins hMSH2 and hMLH1 was investigated in human ovarian cancer cell lines and in biopsies of ovarian carcinomas obtained from 20 patients undergoing surgical operation. By Western blotting analysis hMSH2 protein was detected in all the tumor samples analyzed and in eight out of nine human ovarian cancer cell lines, while hMLH1 was undetectable in four out of 20 ovarian tumors and in five out of nine human ovarian cancer cell lines analyzed. The possible presence of frameshift mutations in the BAX gene, which contains a sequence of eight contiguous guanines in its third exon, was tested in all the samples. All the cell lines presented the normal alleles for the BAX gene while only in one of the tumor samples a heterozygous frameshift mutation was found. The frameshift mutation was associated to a low, almost undetectable, level of BAX protein which was instead present at much higher levels in all the other samples investigated. The results indicate that frameshift mutations in the BAX gene, possibly arising as a consequence of microsatellite instability (detectable in these tumors), is detectable in human ovarian cancer although quantitatively it does not appear to be a major determinant of the low apoptotic response to chemotherapy observed in ovarian cancer cells.

Asunto(s)

Reparación del ADN , Proteínas de Unión al ADN , Mutación del Sistema de Lectura , Proteínas de Neoplasias/genética , Neoplasias Ováricas/genética , Proteínas Proto-Oncogénicas/genética , Proteínas Adaptadoras Transductoras de Señales , Apoptosis/genética , Western Blotting , Proteínas Portadoras , Ciclo Celular/genética , Femenino , Humanos , Homólogo 1 de la Proteína MutL , Proteína 2 Homóloga a MutS , Proteínas Nucleares , Neoplasias Ováricas/patología , Células Tumorales Cultivadas

RESUMEN

A possible novel mechanism of cross-resistance to cisplatin (CDDP) in the doxorubicin-resistant ovarian-cancer cell line A2780-DX3, which displays atypical multidrug resistance, is presented. A2780-DX3 is found to be more resistant than the parental line A2780 in terms of CDDP-induced cytotoxicity and apoptosis. Resistance is not related to the amount of cross-links. Topoisomerase-II (topII) protein levels were similar in both cell lines, with lower cleavage activity in A2780-DX3 cells. The parental and the doxorubicin-resistant cells expressed the same level of c-erb2, which could be implicated in CDDP resistance. bcl2 was almost undetectable in both cell lines. At the same time, we found strong induction of p53, waf-1 and bax protein levels after CDDP treatment in the A2780, but not in the A2780-DX3, cell line. Treatment of both cell lines with mitomycin C (MMC), which acts with a mechanism different from CDDP, caused equal accumulation of p53 and induction of bax. We found that A2780-DX3 cells exhibit altered cellular localization of p53 protein in comparison with A2780. A significant proportion of p53 in A2780-DX3 cells was found in the cytoplasmic compartment, and CDDP treatment induced a functional p53 protein in the nucleus of A2780 much more strongly than in A2780-DX3, which coincides with an increase of transcriptional activity of p53 in treated A2780 cells. We propose that the cross-resistance to CDDP in the A2780-DX3 cell line may be due to inactivation of a CDDP-dependent p53-accumulation pathway.

Asunto(s)

Cisplatino/farmacología , Neoplasias Ováricas/tratamiento farmacológico , Proteína p53 Supresora de Tumor/fisiología , Fragmentación del ADN , Doxorrubicina/farmacología , Resistencia a Antineoplásicos , Femenino , Humanos , Factores de Tiempo , Células Tumorales Cultivadas

RESUMEN

Nine human ovarian cancer cell lines that express wild-type (wt) or mutated p53 were used to evaluate the cytotoxicity induced by paclitaxel. The IC50 calculated in the five mutated p53-expressing cell lines was not different from the four wt p53-expressing cell lines. The introduction of wt p53, by using a temperature-sensitive mutant murine p53 or the human p53 under the control of a tetracycline-dependent promoter, did not change the cytotoxicity of paclitaxel as compared to mock-transfected cells. By using for each cell line the paclitaxel IC50, we found that these concentrations were sufficient to induce an increase in p53 levels in all of the four wt p53-expressing cells, whereas in the mutated p53-expressing cells, the levels were unaffected. This increase in p53 levels led to an increase in the mRNA and protein levels of p53 downstream genes (WAF1, GADD45, and bax). In none of the cell lines examined was paclitaxel able to induce apoptosis, evaluated by terminal deoxynucleotidyl transferase-mediated nick end labeling staining and filter binding assay at concentrations closed to the IC50. By increasing the concentration of paclitaxel in the filter binding assay, we could see fragmentation of DNA in the different cell lines. We conclude that the presence of p53 is not a determinant for the cytotoxicity induced by paclitaxel in human ovarian cancer cell lines. Differences in the activation of p53 downstream genes could be observed in wt versus mutated p53-expressing cells, but this does not account either for a differential induction of apoptosis or for a change in cytotoxicity induced by paclitaxel.

Asunto(s)

Apoptosis/efectos de los fármacos , Carcinoma/fisiopatología , Regulación Neoplásica de la Expresión Génica/efectos de los fármacos , Neoplasias Ováricas/fisiopatología , Paclitaxel/toxicidad , Proteínas Proto-Oncogénicas c-bcl-2 , Proteína p53 Supresora de Tumor/fisiología , Carcinoma/tratamiento farmacológico , Supervivencia Celular/efectos de los fármacos , Inhibidor p21 de las Quinasas Dependientes de la Ciclina , Ciclinas/genética , Fragmentación del ADN/efectos de los fármacos , Relación Dosis-Respuesta a Droga , Femenino , Genes p53 , Humanos , Péptidos y Proteínas de Señalización Intracelular , Neoplasias Ováricas/tratamiento farmacológico , Proteínas/genética , Proteínas Proto-Oncogénicas/genética , ARN Mensajero/genética , Células Tumorales Cultivadas , Proteína X Asociada a bcl-2 , Proteinas GADD45

RESUMEN

DNA topoisomerase IIalpha is an essential enzyme for chromosome segregation during mitosis. Consistent with a cell division-specific role, the expression of the topoisomerase IIalpha gene is strongly influenced by the proliferation status of cells. The p53 protein is one of the most important regulators of cell cycle progression in mammals, with an apparent dual role in the induction of cell cycle arrest following cytotoxic insults and in the regulation of the apoptotic cell death pathway. We have analysed whether p53 plays a role in regulating expression of the human topoisomerase IIalpha gene. We show that wild-type, but not mutant, p53 is able to decrease substantially the activity of the full length topoisomerase IIalpha gene promoter. Using a series of constructs comprising various deleted or mutated versions of the promoter lacking critical cis-acting elements, we show that this p53-specific regulation of the topoisomerase IIalpha promoter is independent of all characterised transcription factor binding sites and is directed at the minimal gene promoter. We conclude that expression of wild-type p53 induces downregulation of the human topoisomerase IIalpha promoter by acting on the basal transcription machinery. These findings implicate topoisomerase II as one of the downstream targets for p53-dependent regulation of cell cycle progression in human cells.

Asunto(s)

Antígenos de Neoplasias/genética , ADN-Topoisomerasas de Tipo II/genética , Isoenzimas/genética , Regiones Promotoras Genéticas , Proteína p53 Supresora de Tumor/metabolismo , Línea Celular , Proteínas de Unión al ADN , Regulación hacia Abajo , Femenino , Humanos , Neoplasias Ováricas , Células Tumorales Cultivadas

RESUMEN

The expression of cyclins, cyclin-dependent kinases (cdk), and cdk inhibitors was evaluated in clones from a human ovarian cancer cell line transfected with a temperature-sensitive mutant of p53, after treatment with the anticancer agents doxorubicin (DX) and AMSA. The two drugs were selected on the basis of their activity in these clones, since AMSA is equally active in cells expressing mutated or wild-type (wt) p53, while DX was much less cytotoxic in cells expressing wt p53. In untreated cells, the expression of wt p53 induced an accumulation of cells in the G2 and perhaps also the G1 phase of the cell cycle. Concomitantly cyclin B1 and cdc2 increased. Cyclin E and particularly D1 levels were also raised by wt p53 expression. Treatment of mutated p53-expressing cells (SK23a cells kept at 37 degrees C) with DX or, more so, with AMSA, resulted in a strong accumulation of cyclin B1 and cdc2, in accordance with their ability to block cells in G2 phase of the cell cycle. Wt p53-expressing cells (SK23a cells kept at 32 degrees C) treated with the drugs showed an increase in p21 expression and consequently decreased kinase activity after immunoprecipitation with p21 antibodies. Cdc2-associated kinase activity was also reduced in these conditions. We could also observe a decrease in the percentage of cells in G1 and G2 phases and an accumulation of cells in S phase after both DX and AMSA. Cdk2, retinoblastoma, and p27 levels did not change significantly. Treatment with DX or AMSA caused similar effects, suggesting that p53-induced changes in cyclin, cdk, and cdk inhibitors after DNA damage are not responsible for the marked reduction in the cytotoxicity of DX we observed in wt p53-expressing cells.

Asunto(s)

Ciclina B , Quinasas Ciclina-Dependientes/metabolismo , Ciclinas/metabolismo , Daño del ADN , ADN de Neoplasias/efectos de los fármacos , Proteína p53 Supresora de Tumor/genética , Amsacrina/farmacología , Antibióticos Antineoplásicos/farmacología , Antineoplásicos/farmacología , Northern Blotting , Proteína Quinasa CDC2/genética , Proteína Quinasa CDC2/metabolismo , Ciclina B1 , Ciclina D1 , Quinasas Ciclina-Dependientes/genética , Ciclinas/genética , Doxorrubicina/farmacología , Femenino , Regulación Neoplásica de la Expresión Génica/fisiología , Humanos , Mutación/fisiología , Proteínas Oncogénicas/genética , Proteínas Oncogénicas/metabolismo , Neoplasias Ováricas , Células Tumorales Cultivadas/efectos de los fármacos , Células Tumorales Cultivadas/enzimología

RESUMEN

BACKGROUND: The cytotoxicity and gene expression induced by anticancer drugs with different mechanisms of action was tested in clones from a human ovarian cancer cell line expressing no p53, mutated p53 or wild type (wt) p53. MATERIALS AND METHODS: We used clones from SKOV3 cells transfected with a temperature-sensitive mutant p53 which expresses mutated p53 at 37 degrees C and a wild type-like p53 at 32 degrees C. Cytotoxicity and expression of p53-related genes (WAF1 and GADD45) were tested after 24 hours of treatment with different drugs. RESULTS: All of the drugs were equally active in the different systems, independently of the presence of p53, with the exception of doxorubicin which was less cytotoxic in cells expressing a wtp53. An increase in the transcription of WAF1 and GADD45 genes was found in cells expressing p53 and treated with the drugs. GADD45 and WAF1 expression was also found in cells not expressing p53 but treated with the drugs, suggesting that these genes can also be activated by DNA damage through a pathway independent of p53. A highly DNA-sequence-specific alkylator, tallimustine (FCE 24517), which causes a very small number of DNA lesions, does not increase the expression of these genes. Cyclin D1 gene expression was not changed after treatment with the drugs tested in cells both expressing and not expressing wtp53. CONCLUSIONS: Our data suggest that p53 expression does not play a role in increasing the susceptibility of cells not undergoing apoptosis after DNA damage, but that, at least in the case of doxorubicin, it can enhance the repair systems and reduce the cytotoxicity.

Asunto(s)

Antineoplásicos/farmacología , Neoplasias Ováricas/tratamiento farmacológico , Secuencia de Bases , Northern Blotting , Western Blotting , Daño del ADN , Ensayos de Selección de Medicamentos Antitumorales , Femenino , Expresión Génica/efectos de los fármacos , Genes p53/efectos de los fármacos , Humanos , Datos de Secuencia Molecular , Neoplasias Ováricas/genética , Reacción en Cadena de la Polimerasa , Antígeno Nuclear de Célula en Proliferación/análisis , Antígeno Nuclear de Célula en Proliferación/efectos de los fármacos , ARN Mensajero/efectos de los fármacos , Transfección , Células Tumorales Cultivadas

RESUMEN

The cytotoxicity of Doxorubicin and cis-dichloro-diammine-platinum (DDP) was evaluated in clones, obtained from a human ovarian cancer cell line transfected with a temperature-sensitive p53 mutant, which express mutant p53 at 37 degrees C and wild-type-like p53 at 32 degrees C. DDP was equally active in cells not expressing p53 (SKN) or cells expressing a mutated form of p53 (SK23a kept at 37 degrees C) or a wild-type-like form of p53 (SK23a cells kept at 32 degrees C). In contrast, Doxorubicin was less cytotoxic in cells expressing wild-type p53 than in cells expressing no p53 or mutated p53. This reduction was not due to a decreased intracellular accumulation or to a faster efflux of Doxorubicin. Topoisomerase II was found to be present in the same amount in all the systems utilized and to be functionally active, thus not accounting for the observed effect of Doxorubicin. A clear induction of WAF1/CIP1 and GADD45 genes in cells expressing wild-type p53 after Doxorubicin treatment was found. DDP, which was equally active in the cells utilized, caused an increase in the transcription only of GADD45 gene but not of WAF1/CIP1 gene. Doxorubicin was also able to induce the transcription of WAF1/CIP1 gene in SKN cells (not expressing p53) or in SK23a cells at 37 degrees C (expressing mutated p53), indicating that the expression of this gene also, in some tumor-cell lines, is not necessarily or uniquely induced by wild-type p53.

Asunto(s)

Supervivencia Celular/efectos de los fármacos , Cisplatino/toxicidad , Ciclinas/biosíntesis , Doxorrubicina/toxicidad , Expresión Génica , Genes p53 , Inhibidores de Proteínas Quinasas , Proteínas , Northern Blotting , Línea Celular , Inhibidor p21 de las Quinasas Dependientes de la Ciclina , Daño del ADN , ADN-Topoisomerasas de Tipo II/metabolismo , Relación Dosis-Respuesta a Droga , Femenino , Humanos , Péptidos y Proteínas de Señalización Intracelular , Neoplasias Ováricas , Biosíntesis de Proteínas , ARN Neoplásico/análisis , ARN Neoplásico/biosíntesis , Células Tumorales Cultivadas , Proteinas GADD45

RESUMEN

Utilizing a temperature sensitive p53 mutant (pLTRp53cGval135) which expresses mutant p53 at 37 degrees C and a wild-type like p53 at 32 degrees C, we transfected a human ovarian cancer cell line (SKOV3) which does not express endogenous p53. Among the different clones obtained, we selected three clones. Two were obtained from simultaneous transfection of p53 and neomycin resistance expression plasmids (SK23a and SK9), the other was obtained from transfection experiments utilizing the neomycin resistance gene only (SKN). Introduction of mutant p53 did not alter the morphology or growth characteristics of this ovarian cancer cell line. Upon shifting to the permissive temperature, a dramatic change in morphology and growth rate was observed in SK23a and SK9 cells that is associated with the presence of a wild-type like p53. SKN and SKOV3 cells maintained at 32 degrees C did not change morphology and only slightly reduced proliferation. Both SK23a and SK9 cells did not show evidence of apoptosis when measured up to 72 hours of maintenance at 32 degrees C. In contrast to what observed in other cell lines, SK23a and SK9 cells maintained at 32 degrees C were not blocked in G1, but they were accumulated in G2-M. This accumulation was transient and could be due either to a blockade or to a delay in the G2 progression. No down-regulation of c-myc was observed in p53 expressing clones when shifted to the permissive temperature. In these conditions gadd45 mRNA expression was highly stimulated in SK9 and SK23a cells but not in SKN cells. In both clones Gas1 mRNA was not detected either at 37 degrees C or 32 degrees C. This system represents a new and useful model for studying the effect of the absence of p53 (SKOV3 or SKN), presence of mutated p53 (SK23a and SK9 kept at 37 degrees C) or wild type p53 (SK23a and SK9 kept at 32 degrees C) on the mechanism of response of cancer cells to DNA damaging agents.

Asunto(s)

Genes p53 , Neoplasias Ováricas/genética , Transfección , Animales , Apoptosis , División Celular , Resistencia a Medicamentos/genética , Femenino , Citometría de Flujo , Técnica del Anticuerpo Fluorescente , Humanos , Ratones , Mutación , Neomicina , Neoplasias Ováricas/patología , Plásmidos , ARN Mensajero/metabolismo , Temperatura , Células Tumorales Cultivadas

RESUMEN

Inhibition of clonogenic potential by the glycinamideribonucleosyl transformylase inhibitor 5,10-dideazatetrahydrofolic acid (DDATHF, Lometrexol) was evaluated in vitro in a human ovarian carcinoma cell line, SW626. Drug-induced inhibition of clonogenic potential is a function of the dose and time of exposure and is independent of the formation of DNA single-strand breaks or de novo synthesis of protein. Simultaneous treatment with 100 microM hypoxanthine completely prevented the inhibition of clonogenic potential caused by 0.5 microM DDATHF. DDATHF blocked cells in the early-middle S-phases of the cell cycle, and there was a corresponding marked reduction in the rate of DNA synthesis after drug withdrawal. The cytotoxic potential of DDATHF was modulated by the folic acid concentration present in the medium. In a medium containing 0.22 microM folic acid, DDATHF cytotoxicity was at least 100 times that in a regular medium containing 2.22 microM folic acid, levels which, however, are about 100 times those found in human plasma. DDATHF cytotoxicity differed moderately when folic acid concentrations varied between 0.22 and 0 microM, suggesting that folic acid does not necessarily antagonise DDATHF anti-tumour activity. Folinic acid at a concentration as low as 0.1 microM can completely rescue cells when given simultaneously with 0.5 microM DDATHF. When folinic acid was given 24 h after DDATHF, a reversal of cytotoxicity was observed at 0.5 and 1 microM, but to a much lesser extent than simultaneous treatment. When folinic acid was added after 48 or 72 h of DDATHF washout, even at a high concentration and for a long time, no reduction in DDATHF cytotoxicity was found. In conclusion, the study highlights the modulation of DDATHF cytotoxicity by folic acid or by folinic acid and provides further rationale for in vivo clinical investigation with these combinations.

Asunto(s)

Antineoplásicos/farmacología , Antagonistas del Ácido Fólico/farmacología , Ácido Fólico/farmacología , Leucovorina/farmacología , Tetrahidrofolatos/farmacología , Antineoplásicos/administración & dosificación , Antineoplásicos/antagonistas & inhibidores , Ciclo Celular/efectos de los fármacos , ADN de Neoplasias/biosíntesis , ADN de Neoplasias/efectos de los fármacos , Ensayos de Selección de Medicamentos Antitumorales , Femenino , Antagonistas del Ácido Fólico/administración & dosificación , Humanos , Hipoxantina , Hipoxantinas/metabolismo , Neoplasias Ováricas/metabolismo , Neoplasias Ováricas/patología , Tetrahidrofolatos/administración & dosificación , Tetrahidrofolatos/antagonistas & inhibidores , Timidina/biosíntesis , Factores de Tiempo , Células Tumorales Cultivadas/metabolismo , Células Tumorales Cultivadas/patología